3D chromosomal landscape reveals miR-146a dysfunctional enhancer in lupus and establishes a CRISPR-mediated approach to inhibit the IFN pathway.


Journal

Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795

Informations de publication

Date de publication:
20 Sep 2023
Historique:
revised: 28 08 2023
received: 05 02 2023
accepted: 07 09 2023
medline: 20 9 2023
pubmed: 20 9 2023
entrez: 20 9 2023
Statut: aheadofprint

Résumé

The diminished expression of miR-146a in SLE contributes to the aberrant activation of the interferon pathway. Despite its significance, the underlying mechanism driving this reduced expression remains elusive. Considering the integral role of enhancers in steering gene expression, our study seeks to pinpoint the SLE-affected enhancers responsible for modulating miR-146a expression. Additionally, we aim to elucidate the mechanisms by which these enhancers influence miR-146a's contribution to the activation of interferon pathway. 4C-seq and epigenomic profiles were applied to identify candidate enhancers of miR-146a. CRISPR activation was performed to screen functional enhancers. Differential analysis of chromatin accessibility was utilized to identify SLE-dysregulated enhancers and the mechanism underlying enhancer dysfunction was investigated by analyzing transcription factor binding. The therapeutic value of a lupus-related enhancer was further evaluated by targeting it in SLE patients' PBMCs through CRISPR activation approach. We identified shared and cell-specific enhancers of miR-146a in distinct immune cells. An enhancer, 32.5 kb downstream of miR-146a, possesses less accessibility in SLE, and its chromatin openness was negatively correlated with SLE disease activity. Moreover, C/EBPα, a down-regulated transcription factor in SLE patients, binds to the 32.5-kb enhancer and induces the epigenomic change of this locus. Furthermore, CRISPR-based activation of this enhancer in SLE PBMCs could inhibit the activity of interferon pathway. Our work defines a promising target for SLE intervention. We adopted integrative approaches to define cell-specific and functional enhancers of the SLE critical gene, and investigated the mechanism underlying its dysregulation mediated by a lupus-related enhancer.

Identifiants

pubmed: 37728419
doi: 10.1002/art.42703
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

This article is protected by copyright. All rights reserved.

Auteurs

Xinyi Zhu (X)

Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, 200001.
Shenzhen Futian Hospital for Rheumatic Diseases, Shenzhen, China, 518040.
State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, 200032.

Yutong Zhang (Y)

Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, 200001.

Zihang Yin (Z)

Sheng Yushou Center of Cell Biology and Immunology, Joint International Research Laboratory of Metabolic & Developmental Sciences, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University (SJTU), Shanghai, China, 200240.

Zhizhong Ye (Z)

Shenzhen Futian Hospital for Rheumatic Diseases, Shenzhen, China, 518040.

Yuting Qin (Y)

Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, 200001.

Zhaorui Cheng (Z)

Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, 200001.

Yiwei Shen (Y)

Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, 200001.

Zhihua Yin (Z)

Shenzhen Futian Hospital for Rheumatic Diseases, Shenzhen, China, 518040.

Jianyang Ma (J)

Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, 200001.

Yuanjia Tang (Y)

Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, 200001.

Huihua Ding (H)

Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, 200001.

Ya Guo (Y)

Sheng Yushou Center of Cell Biology and Immunology, Joint International Research Laboratory of Metabolic & Developmental Sciences, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University (SJTU), Shanghai, China, 200240.

Guojun Hou (G)

Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, 200001.
Shenzhen Futian Hospital for Rheumatic Diseases, Shenzhen, China, 518040.
State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, 200032.

Nan Shen (N)

Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, 200001.
Shenzhen Futian Hospital for Rheumatic Diseases, Shenzhen, China, 518040.
State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, 200032.
Center for Autoimmune Genomics and Etiology, Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA, 45229.
Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA, 45229.

Classifications MeSH